Phg Technologies, LLC v. St. John Companies, Inc.

469 F.3d 1361, 81 U.S.P.Q. 2d (BNA) 1088, 2006 U.S. App. LEXIS 28468, 2006 WL 3334937
Court of Appeals for the Federal Circuit·Decided November 17, 2006·No. 06-1169·Published·Cited by 42 cases

Opinion

PROST, Circuit Judge.

Defendant-Appellant, St. John Companies, Inc. (“St.John”), appeals the decision *1363 of the United States District Court for the Middle District of Tennessee granting a preliminary injunction in favor of Plaintiff-Appellee, PHG Technologies, L.L.C. (“PHG”). Because we find that St. John has raised a substantial question of the validity of the two patents at issue, the district court abused its discretion by granting PHG’s motion for a preliminary injunction. Therefore, we vacate the preliminary injunction.

I. BACKGROUND

PHG and its predecessors have been in the business of selling certain medical patient identification labels as well as identification labeling software in the United States since 1995. PHG owns the two design patents at issue in this case: United States Patent Nos. D496,405 (the “'405 patent”) and D503,197 (the “'197 patent”). The '405 patent claims “[t]he ornamental design for the medical label sheet, as shown.” The '197 patent claims “[t]he ornamental design for a label pattern for a medical label sheet, as shown.” Figure 1 from the '405 patent and figure 1 from the '197 patent appear below, respectively:

FiG. 1

[[Image here]]

As can be seen, both designs include eleven rows of labels, with each row containing three labels. The first nine rows are depicted to contain three labels of equal size, the size being consistent with a standard medical chart label. The tenth and eleventh row each contain differently-sized labels which apparently correspond to the size of a pediatric and adult patient wristband respectively. The difference between the two patents is that the border is part of the design claimed in the '405 patent but not part of the design claimed in the '197 patent. The '405 and '197 patents depend from a utility patent application, No. 09/952,425 (the “'425 utility application”), which is still pending at the United States Patent and Trademark Office.

*1364 St. John also sells medical patient identification labels in the United States in competition with PHG. 1 On May 13, 2004, before PHG’s design patents issued, PHG informed St. John by letter that the design of St. John’s medical label sheet infringed the intellectual property rights of PHG and that PHG anticipated that patents covering the accused design would be issued in the future. St. John did not respond to the May 13th letter and continued to sell its medical label sheet. After the two patents issued, PHG filed suit on August 11, 2005 alleging, inter alia, that St. John’s medical label sheet infringed the '405 and '197 patents.

On August 26, 2005, two weeks after filing suit, PHG moved for a preliminary injunction against St. John’s continued sale of its accused medical label sheet. The district court held an evidentiary hearing on November 22, 2005. St. John argued that the patented medical label sheets are primarily functional and presented evidence from the prosecution history of the '425 utility application and from an affidavit submitted by Adam Press, St. John’s Chief Executive Officer, in support of its argument. PHG presented the testimony of Mr. Moyer, one of the inventors of the patents at issue. Mr. Moyer testified that he and Mr. Stewart, his co-inventor, experimented with different configurations of the medical labels and chose the claimed designs because they were the “most aesthetically pleasing to us.”

On December 5, 2005, the district court granted PHG’s motion for a preliminary injunction and made, inter alia, the following findings with respect to the validity of the patents: (1) the design claimed is not dictated by its function; (2) the different sizes and arrangement of labels on PHG’s claimed design are primarily ornamental because there are other ways to arrange different sizes of labels on an 8 1/2" x 11" sheet; (3) the inventors of the design considered various arrangements and chose the patented design because it had “the best flow and look”; and (4) the novel features of PHG’s designs, particularly the placement of the various sizes of labels at the bottom of the sheet, distinguishes PHG’s designs from the prior art. Additionally, the district court made the following findings pertaining to infringement of the patents by St. John’s medical label sheet: (1) when compared, St. John’s medical label sheet and the patented design are identical and an ordinary observer would be “very hard-pressed” to identify any differences in the two designs; and (2) St. John’s accused design appropriates the novelty of PHG’s patented design, which distinguishes it from the prior art — the different sizes of labels and their placement on the sheet. Finally, the district court found that PHG is entitled to a rebuttable presumption of irreparable harm and the evidence confirms that PHG has suffered and will continue to suffer substantial damage in lost sales, business opportunities, and customer goodwill if St. John is not enjoined from continuing to market its accused design. See PHG Techs., L.L.C. v. St. John Cos., No. 03:05-0630 (M.D.Tenn. Dec. 5, 2005) (“Preliminary Injunction Opinion”). Based on these findings, the court concluded that PHG demonstrated a reasonable likelihood of success on the merits, established that it would be irreparably harmed if an injunction did not issue and showed. that the balance of hardships and the public inter *1365 est weigh in favor of enjoining St. John from continuing to sell its accused design.

St. John appeals the district court’s grant of the preliminary injunction against its accused medical label sheet design. We have jurisdiction pursuant to 28 U.S.C. § 1292(a)(1).

II. DISCUSSION

A. Standard of Review

This court reviews a district court’s decision granting a motion for preliminary injunction for an abuse of discretion. Novo Nordisk of N. Am., Inc. v. Genentech, Inc., 77 F.3d 1364, 1367 (Fed.Cir.1996). “To overturn the grant of a preliminary injunction, we must find that the district court made a clear error of judgment in weighing the relevant factors or based its exercise of discretion on an error of law or on clearly erroneous factual findings.” Pfizer, Inc. v. Teva Pharms., USA Inc., 429 F.3d 1364, 1372 (Fed.Cir.2005). Whether a patented design is functional or ornamental is a question of fact.

Free access — add to your briefcase to read the full text and ask questions with AI

Phg Technologies, LLC v. St. John Companies, Inc., 469 F.3d 1361, 81 U.S.P.Q. 2d (BNA) 1088, 2006 U.S. App. LEXIS 28468, 2006 WL 3334937 (Fed. Cir. 2006).

469 F.3d 1361 (Phg Technologies, LLC v. St. John Companies, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related